Wednesday, July 8, 2026

Patent intelligence · US

US 6066639

5,6,7,8-tetrahydropyrido[2,3-D]pyrimidines

expired A61KA61K38/00
Status expired
Linked drugs 3
Pipeline programs 1
Years to expiry 0
Applicant portfolio 163
Patent details — US 6066639

Quick answer

US 6066639 (5,6,7,8-tetrahydropyrido[2,3-D]pyrimidines) is held by THE TRUSTEES OF PRINCETON UNIVERSITY. Status: expired. Granted May 23, 2000. Expires May 18, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
15
CPC classes
A61K, A61K38/00

More from THE TRUSTEES OF PRINCETON UNIVERSITY

Related pharmaceutical patents in our USPTO index.

  1. US 12419831

    Hydrocortisone oral liquid formulations

    Eton Pharmaceuticals, Inc. · Expires Sep 18, 2045

    granted
  2. US 12396974

    Ketone ester as a therapeutic treatment of Covid-19 and related viral infections

    KetoneAid · Expires Aug 21, 2045

    granted
  3. US 12357582

    Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jul 10, 2045

    granted
  4. US 12343324

    Dihydromyricetin hot melt extrusion formulations and methods for forming them

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jun 26, 2045

    granted
  5. US 12329816

    Immunotherapy with metabolic enzyme expression

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jun 12, 2045

    granted
  6. US 12209256

    System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jan 23, 2045

    granted
  7. US 12195768

    System and method for modulating stress granule assembly

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jan 9, 2045

    granted
  8. US 12186436

    Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents

    THE TRUSTEES OF PRINCETON UNIVERSITY · Expires Jan 2, 2045

    granted

Frequently asked questions

What is US patent 6066639?

US 6066639 (5,6,7,8-tetrahydropyrido[2,3-D]pyrimidines) is held by THE TRUSTEES OF PRINCETON UNIVERSITY. Status: expired. Granted May 23, 2000. Expires May 18, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6066639?

THE TRUSTEES OF PRINCETON UNIVERSITY is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 163 pharmaceutical patents for this assignee.

When does US 6066639 expire?

Our index shows an expiration date of May 18, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.